NuCana (NCNA) Expected to Announce Quarterly Earnings on Thursday

NuCana (NASDAQ:NCNA) is expected to be posting its results before the market opens on Thursday, March 19th. Analysts expect NuCana to post earnings of ($2.6944) per share for the quarter.

NuCana Trading Down 0.5%

NASDAQ NCNA opened at $1.90 on Tuesday. The stock has a market capitalization of $57,000.00, a price-to-earnings ratio of -0.01 and a beta of 1.69. The stock has a 50-day moving average of $2.55 and a 200 day moving average of $3.48. NuCana has a twelve month low of $1.88 and a twelve month high of $268.00.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a research note on Thursday, January 22nd. Wall Street Zen raised shares of NuCana from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.